Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial

Core Viewpoint - Intellia Therapeutics Inc. shares have risen following the FDA's decision to lift the clinical hold on its MAGNITUDE Phase 3 clinical trial, which is crucial for the development of its treatment for transthyretin amyloidosis with cardiomyopathy [1][3] FDA Decision - The FDA has removed the clinical hold on Intellia's Investigational New Drug application for the MAGNITUDE trial, which assesses the efficacy and safety of nexiguran ziclumeran (nex-z) [3] - The clinical holds were initially imposed in October 2025 due to safety concerns related to liver transaminases and bilirubin levels in trial participants [1][4] Trial Details - The MAGNITUDE trial aims to enroll approximately 1,200 patients with ATTR-CM, while the MAGNITUDE-2 trial focuses on around 60 patients with hereditary ATTR amyloidosis with polyneuropathy [5] - New exclusion criteria for MAGNITUDE include patients with recent cardiovascular instability and those with an ejection fraction below 25% [5] Market Reaction - Intellia's stock is currently trading 8.85% above its previous close, reflecting a strong positive reaction to the FDA news [6] - Over the past 12 months, shares have increased by 20%, indicating a favorable long-term trend [6] Technical Analysis - The Relative Strength Index (RSI) is at 50.00, suggesting neutral market conditions, while the Moving Average Convergence Divergence (MACD) is at 0.10, indicating some bearish pressure [6][7] Analyst Consensus - The stock carries a Buy Rating with an average price target of $19.73, with recent analyst actions including a maintained target of $26.00 by Chardan Capital and a raised target of $25.00 by HC Wainwright & Co. [8]